Accredo Health Group, Inc. is a specialty pharmacy provider focused on delivering personalized care and support for patients managing complex and chronic health conditions across the United States.
The company operates 15 condition-specific Therapeutic Resource Centers (TRCs) that provide clinical expertise in areas including oncology, neurology and multiple sclerosis, immunology, infectious diseases such as HIV and hepatitis C, bleeding disorders, cystic fibrosis, and rare diseases. Services encompass access to over 500 specialty-trained pharmacists, more than 600 infusion nurses for in-home care, therapy management programs, nutrition support, medication adherence initiatives, insurance coordination, and convenient home delivery of specialty medications.
Accredo partners with pharmaceutical manufacturers for limited and exclusive distribution of high-cost therapies and supports patient access programs. It operates nationwide with a network of care delivery sites and clean rooms for preparing complex therapies. The company is a wholly owned subsidiary of Express Scripts and functions as part of Evernorth Health Services within The Cigna Group, positioning it as a leading integrated specialty pharmacy in the U.S. healthcare industry with emphasis on clinical outcomes, cost management, and coordinated care.
Also known as Accredo Specialty Pharmacy and Accredo by Evernorth.
None yet. When a new project in the record names Accredo as owner, partner or investor, it shows here.
The oral OX2R agonist is a Schedule IV controlled substance and will be dispensed through Accredo Specialty Pharmacy.
